---
title: "里昂：升康龍化成目標價至 28.8 港元 維持 “跑贏大市” 評級"
description: "里昂發佈研報稱，康龍化成 (03759，將 2025 年營收增長指引由同比增 10% 至 15%，上調至 12 至 16%，並預期經調整非國際財務報告準則淨利潤將實現雙位數增長。該行認為對今年末季至明年而言，康龍化成上調指引及積存訂單增加屬可喜。里昂上調康龍化成 2025 至 2027 年營收與淨利預測，H 股目標價由 24.7 港元升至 28.8 港元，A 股目標價由 34.8 元人民幣升至 4"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/263667131.md"
published_at: "2025-10-31T06:12:04.000Z"
---

# 里昂：升康龍化成目標價至 28.8 港元 維持 “跑贏大市” 評級

> 里昂發佈研報稱，康龍化成 (03759，將 2025 年營收增長指引由同比增 10% 至 15%，上調至 12 至 16%，並預期經調整非國際財務報告準則淨利潤將實現雙位數增長。該行認為對今年末季至明年而言，康龍化成上調指引及積存訂單增加屬可喜。里昂上調康龍化成 2025 至 2027 年營收與淨利預測，H 股目標價由 24.7 港元升至 28.8 港元，A 股目標價由 34.8 元人民幣升至 40.6 元人民幣，均維持 “跑贏大市” 評級。

智通財經 APP 獲悉，里昂發佈研報稱，康龍化成 (03759,300759.SZ) 將 2025 年營收增長指引由同比增 10% 至 15%，上調至 12 至 16%，並預期經調整非國際財務報告準則淨利潤將實現雙位數增長。該行認為對今年末季至明年而言，康龍化成上調指引及積存訂單增加屬可喜。里昂上調康龍化成 2025 至 2027 年營收與淨利預測，H 股目標價由 24.7 港元升至 28.8 港元，A 股目標價由 34.8 元人民幣升至 40.6 元人民幣，均維持 “跑贏大市” 評級。

### Related Stocks

- [300759.CN - 康龍化成](https://longbridge.com/zh-HK/quote/300759.CN.md)
- [03759.HK - 康龍化成](https://longbridge.com/zh-HK/quote/03759.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Pharmaron To Raise HK$1.3 Billion in Share Placement | Pharmaron Beijing Co Ltd :SAYS IT PLANS TO PLACE 58.4 MILLION NEW H-SHARES AT HK$22.82 PER SHARESAYS IT EXPECTS TO RAISE | [Link](https://longbridge.com/zh-HK/news/272620883.md) |
| Pharmaron Beijing Announces Private Placement of 58 Million New H Shares | Pharmaron Beijing Co. Ltd. has announced a private placement of 58,440,762 new H shares under its general issuance manda | [Link](https://longbridge.com/zh-HK/news/272610619.md) |
| TAV Airports FY Net Profit Shrinks To 2.82 Bln Lira YOY, Proposes To Pay Dividend At Gross 3.61 Lira Per Share, Announces 2026 Guidance | TAV Airports reported a FY net profit of 2.82 billion lira, down from 6.56 billion lira year-over-year. The company's re | [Link](https://longbridge.com/zh-HK/news/276201362.md) |
| Pharmaron Acquires Majority Stake in Biortus for RMB1.3 Billion | Pharmaron Beijing Co., Ltd. has acquired an 82.54% stake in Biortus for approximately RMB1.3 billion, making Biortus a s | [Link](https://longbridge.com/zh-HK/news/263101055.md) |
| Pharmaron Raises HK$1.32 Billion via H-Share Placement to Fund Capacity Expansion | Pharmaron Beijing Co., Ltd. has raised approximately HK$1.32 billion through the placement of 58,440,762 new H shares at | [Link](https://longbridge.com/zh-HK/news/273351963.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。